alpha-aminopyridine has been researched along with Neuroendocrine Tumors in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Rahman, O; de Sousa, MJ; Fazio, N; Gervaso, L; Meneses-Medina, MI; Spada, F | 1 |
| Bou-Ayache, J; Chaft, J; Chan, J; Chou, J; Hauser, H; Perez, K; Rafailov, J; Raj, N; Reidy-Lagunes, D; Rudin, C; Sawan, P; Tang, L; Zheng, Y | 1 |
| Aboukameel, A; Al-Hallak, MN; Azmi, AS; Baloglu, E; Beydoun, R; Dyson, G; El-Rayes, BF; Kim, SH; Landesman, Y; Li, Y; Mohammad, RM; Mpilla, GB; Philip, PA; Senapedis, WT; Uddin, MH; Viola, NT; Wagner, KU | 1 |
| Anthony, L; Campbell, K; Elliott, VA; Evers, BM; Harris, JW; Kim, JT; Li, J; Mustain, WC; Song, J; Townsend, CM; Valentino, JD; Wang, C; Weiss, H; Zaytseva, YY | 1 |
| Aristizabal Prada, ET; Auernhammer, CJ; Maurer, J; Nölting, S; Spoettl, G | 1 |
| Chang, RP; Giaccone, G; Harada, T; Killian, JK; Lucchi, M; Meltzer, PS; Smith, WI; Suuriniemi, M; Voortman, J; Wang, Y | 1 |
1 review(s) available for alpha-aminopyridine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Lung Neoplasms; Neuroendocrine Tumors; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
5 other study(ies) available for alpha-aminopyridine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.
Topics: Aminopyridines; Everolimus; Humans; Middle Aged; Neuroendocrine Tumors; Purines | 2021 |
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cytokines; Drug Therapy, Combination; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred ICR; Mice, SCID; Neuroendocrine Tumors; Nicotinamide Phosphoribosyltransferase; p21-Activated Kinases; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Drug Synergism; Humans; Imidazoles; Male; Mice; Mitogen-Activated Protein Kinases; Morpholines; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Topics: Aminopyridines; Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Everolimus; Fluorouracil; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; Purines; Time Factors | 2018 |
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Humans; Indoles; Lung Neoplasms; Mutation; Neuroendocrine Tumors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-met; Pyridones; Small Cell Lung Carcinoma; Sulfonamides | 2013 |